Maintenance rituximab extended PFS, not OS in follicular lymphoma Healio Patients with follicular lymphoma who achieved stable disease with rituximab-based induction therapy demonstrated extended PFS and time to next treatment when they received maintenance rituximab, according to results of a prospective, observational ... |
